RESEARCH TRIANGLE PARK – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company developing treatments for rare diseases, reported Thursday that the European Medicines Agency (EMA) has approved its flu treatment, peramivir (ALPHIVAB).

It is a single intravenous infusion for the treatment of uncomplicated influenza in adults and children from the age of 2 years.

“ALPIVAB approval in the European Union represents a significant advancement for influenza patients, representing the only single dose I.V. treatment option in the armamentarium for influenza infections,” said Jon P. Stonehouse, BioCryst president and  CEO, in a statement.

The EMA’s approval of ALPIVAB under the centralized licensing procedure provides marketing authorization for all 28-member states of the European Union, Norway and Iceland. It has also received approval for commercialization  of peramivir under various brand names in the U.S., Canada, Australiz, Japan, Taiwan and Korea.

BioCryst has several ongoing development programs.